Publicacións en colaboración con investigadores/as de Emory University (44)

2024

  1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  2. Embolization of percutaneous left atrial appendage closure devices: timing, management and clinical outcomes

    Cardiovascular Revascularization Medicine

  3. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study

    Cancer, Vol. 130, Núm. 6, pp. 886-900

  4. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

  5. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

  6. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

    Blood Advances, Vol. 8, Núm. 1, pp. 194-206

2023

  1. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

    Haematologica, Vol. 108, Núm. 11, pp. 2894-2912

  2. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma

    Cancer, Vol. 129, Núm. 13, pp. 2035-2046

  3. Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1600-1609

  4. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia

    Future Oncology, Vol. 19, Núm. 5, pp. 345-353

  5. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 12, pp. 811-818

2022

  1. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

    The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414

  2. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

    The Lancet Oncology, Vol. 23, Núm. 1, pp. 65-76

  3. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62

  4. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

    British Journal of Haematology

  2. Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

    British Journal of Haematology, Vol. 193, Núm. 3, pp. 561-569

  3. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

    Haematologica, Vol. 106, Núm. 6, pp. 1725-1732

  4. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

2020

  1. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 8, pp. 509-518